Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.

Abstract

Castleman disease is a rare lymphoproliferative disorder, which presents in a unicentric or multicentric fashion. Multicentric Castleman disease (MCD) is associated with significant systemic symptoms, in part related to the underlying role of interleukin-6 in disease pathogenesis. Treatment for MCD has not been well established and prognosis has historically been poor. We present a case of severe MCD in a pediatric patient who has shown sustained remission following multi-agent chemotherapy and targeted maintenance therapy with the interleukin-6 receptor inhibitor, tocilizumab. This represents the first case report of sustained remission of MCD in a pediatric patient following discontinuation of tocilizumab therapy.

• Authors: Lucie M Turcotte, Colleen K Correll, Robyn C Reed, Christopher L Moertel
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 61 Issue 4 Pg. 737-9 (Apr 2014) ISSN: 1545-5017 [Electronic] United States
• PMID: 24019247 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2013 Wiley Periodicals, Inc.

Chemical References

• Antibodies, Monoclonal, Humanized
• Receptors, Interleukin-6
• tocilizumab

Topics

• Adolescent
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Castleman Disease (drug therapy)
• Drug Therapy, Combination
• Humans
• Male
• Prognosis
• Receptors, Interleukin-6 (antagonists & inhibitors)
• Remission Induction